Synaptogenix volatile after FDA OK for Biogen's aducanumab

TAO Synergies

07/06/2021 18:24

** Synaptogenix  SNPX.O  shares down 0.14% at $6.95 after being
halted for volatility twice during the session
    ** Stock has traded between a range of $6.72 at the low and
$9.50 at the high, with large price swings coming on the heels
of FDA approval for Biogen's Alzheimer's disease drug aducanumab
 urn:newsml:reuters.com:*:nL2N2NP12J
    ** Trading volume of ~700,000 already the most active
trading day on record for SNPX, and well above 10-day daily
moving average of ~26k 
    ** SNPX, which develops therapies for neurodegenerative
diseases, said "We applaud the significant commitment that
Biogen has made towards developing a new treatment option for
Alzheimer's Disease." 
    ** Earlier in the session, SNPX said it had been approved to
list on the Nasdaq, beginning Monday, moving from
over-the-counter trading  urn:newsml:reuters.com:*:nPn3WgJqNa

 ((charles.mikolajczak@tr.com; @ChuckMik; Reuters Messaging:
charles.mikolajczak.thomsonreuters.com@reuters.net))